Peter Holst
Owner & Chief Executive & Science Officer Hervolution Therapeutics
Seminars
Tuesday 5th May 2026
Optimizing Tumour Models to Empower Target Validation for IO Therapies
9:30 am
- Identifying and validating target orthologs in mice to ensure accurate immuneoncology efficacy studies
- Employing syngeneic and xenograft mouse models and organoid systems to study tumour growth and immune response dynamics
- Linking the data from these models to elucidate the mode of action of vaccines and guide translational strategies
